Decoy Therapeutics (DCOY) Debt Ratio (2018 - 2026)

Decoy Therapeutics (DCOY) posted quarterly Debt Ratio of 0.02 for Q1 2026, up 31.26% quarter-over-quarter from 0.01 in Q4 2025.

Decoy Therapeutics (DCOY) Debt Ratio (2018 - 2026) Analysis & Trends

Decoy Therapeutics (DCOY) has reported Debt Ratio for 4 consecutive years, with 0.02 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.02; the TTM figure through Mar 2026 stood at 0.02 (changed N/A YoY), while the FY2025 annual figure was 0.01, changed N/A from the prior year.
Debt Ratio improved to 0.02 in Q1 2026 per DCOY's latest filing, from 0.01 in the prior quarter.
Across five years, Debt Ratio topped out at 0.02 in Q1 2026 and bottomed at 0.01 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.57 Bn	131.72 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	0.05
3	Argenx Se	65.44 Bn	60.25 Bn	1.37 Bn	-
4	Moderna	60.06 Bn	54.93 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.89 Bn	28.58 Bn	992.69 Mn	-
7	BioNTech SE	28.11 Bn	9.72 Bn	668.28 Mn	0.03
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.47
10	Decoy Therapeutics	1.73 Mn	1.73 Mn	-	0.02

Download Data